Edgar Filing: MERRIMACK PHARMACEUTICALS INC - Form 4

MERRIMA Form 4 February 11	CK PHARMACH	EUTICAL	S INC						
FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue UNITED STATES STATEMENT O Filed pursuant to Section 17(a) of the			S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940					OMB APPROVAL OMB 3235-0287 Number: January 31, Expires: January 31, 2005 Estimated average burden hours per response 0.5	
(Print or Type 1. Name and A Mulroy Rol	2. Issuer Name and Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC [MACK]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title 0ther (specify below) President and CEO				
(Last) C/O MERR PHARMAO KENDALL B7201	3. Date of Earliest Transaction (Month/Day/Year) 02/09/2015								
(Street) CAMBRIDGE, MA 02139			4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 		
(City)		(Zip)	Tak	da I Non I	Dorivotivo	Socurities A	Person	or Bonoficio	lly Ownod
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ed Date, if	3. Transactio Code (Instr. 8)	4. Securit	ies (A) or of (D)	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect
Reminder: Rep	port on a separate line	e for each cl	ass of sec	urities benet	Perso	ons who res	or indirectly. spond to the colle ained in this form		SEC 1474 (9-02)

information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Date Expiration Date Exercisable (D) Code V (A) Stock Option (1) 02/08/2025 \$ 9.08 02/09/2015 250,000 Α (right to **Reporting Owners Relationships Reporting Owner Name / Address** Director 10% Owner Officer Other Mulroy Robert J. C/O MERRIMACK PHARMACEUTICALS, INC. Х President and CEO ONE KENDALL SQUARE, SUITE B7201 CAMBRIDGE, MA 02139 Signatures /s/ Jeffrey A. Munsie, attorney-in-fact 02/11/2015

Edgar Filing: MERRIMACK PHARMACEUTICALS INC - Form 4

4.

Code

(Instr. 8)

Execution Date, if

(Month/Day/Year)

5. Number of

Disposed of (D)

(Instr. 3, 4, and

Securities Acquired (A) or

TransactionDerivative

5)

6. Date Exercisable and

Expiration Date

(Month/Day/Year)

7. Title and Amount of

Amount or

Number of

250,000

Shares

Underlying Securities

(Instr. 3 and 4)

Title

Common

Stock

3. Transaction Date 3A. Deemed

any

(Month/Day/Year)

If the form is filed by more than one reporting person, see Instruction 4(b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

This option vests as to 1/12th of the total number of shares on 5/9/15 and an additional 1/12th of the total number of shares at the end of (1)each successive three month period thereafter until 2/9/18.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

1. Title of

Security

(Instr. 3)

buy)

Derivative

2

Conversion

or Exercise

Derivative

**Signature of Reporting Person

Explanation of Responses:

Price of

Security